Sign Up to Receive the Latest Trading Tips and News from Prosper

    May 20, 2020

    Why I Took the Breakout in Moderna

    Today I breakdown what I look at on breakout opportunities at highs. These are very risky but rewarding opportunities. The “edge” is always finding the small signs that can help you get on the correct side more often. When it works out in your favor, you tend to be sitting pretty with faster gains in […]

    Read Article
    June 21, 2019

    Is Incyte Corporation Set To Explode?

    We have a very promising bullish technical set up in Incyte Corporation (Ticker: INCY).  It is based on a swing break out formation. Click the video below as I explain the setup and how we used options to further increase our edge. Follow me on Twitter: @MikeShorrCBOT

    Read Article
    May 30, 2019

    Some Insight into Incyte

    This “insight” is regarding technical analysis versus what the company may offer regarding drugs. Yes INCY is a drug maker. The more interesting aspect is the sector in general. The sector has been under fire with the government pushing to stop price gouging. With drug pricing reaching insane levels, the drugmakers took a big hit […]

    Read Article
    March 21, 2019

    BIIB Goes Bye-Bye

    Biogen is having a bad day. The investors (the new ones anyway) are feeling the reeling pain of investing into biotech names. This is the truth of reward to risk. When you play in high-beta names as an investor, unfortunately, this can be an outcome. Biogen (Ticker: BIIB) is discontinuing their Alzheimer drug trial. During […]

    Read Article
    March 11, 2019

    An Angel Swoops In For Seres

    Shares of Seres Therapeutics Inc. (MCRB) were up strongly after news of a collaboration deal with AstraZeneca. In the collaboration deal, MCRB will receive $20M as well as financial support for its research activities in microbiome immuno-oncology. Here’s a recap.

    Read Article
    March 8, 2019

    Earnings Miss Hurts AcelRx

    AcelRx (ACRX) shares slumped in trading today after disappointing earnings results. The company reported $613K in revenue vs. $1.51M consensus estimate. While this was less than half of what was expected, it was not a huge surprise since the company missed revenue estimates by comparable margins over the previous five earnings releases. However, there was […]

    Read Article
    March 7, 2019

    Get the Inside Track On Biotech With Mike Patton

    Here’s a sneak peek of one of the industry’s most reputable, hands-on trading programs with Mike Patton. Grab a free day pass to one of our live signal trading rooms today>>  

    Read Article
    March 7, 2019

    You Want To Talk About A Roller Coaster Ride?

    Bio-Path Holdings Inc (BPTH) shares were up dramatically today, and then they fell very, very quickly. The stock’s price rose from under $3 per share back in late February to over $70 per share. While the company did release a report claiming there BP1001 treatment demonstrated “meaningful clinical improvement”, this is a far cry from […]

    Read Article
    March 5, 2019

    AcelRx Just Waiting For FDA Approval

    AcelRx Pharmaceuticals (ACRX) shares have been up recently as the company awaits an FDA decision on its product Zalviso. Zalviso has already received approval in the European Union, but the FDA previously requested the company to do an additional trial to address certain concerns. AcelRx successfully completed the additional trial and expects the FDA to […]

    Read Article
    March 4, 2019

    Evoke Will Get You Going This Monday!

    Evoke Pharma Inc. (EVOK) shares were down dramatically today after the FDA noted concerns about the company’s product Gimoti, which is currently awaiting FDA approval. Although the FDA’s comments are not indicative of its final conclusion, they nevertheless highlight likely areas of contention over granting approval for the drug, and as a result, investors reacted […]

    Read Article